EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality

Elise De Vos iD, Daniel Westreich iD, Lesley Scott, Yara Voss de Lima iD, Wendy Stevens, Cindy Hayes, Pedro da Silva iD, Annelies Van Rie iD

PLOS Global Public Health · 01.09.2023 · 3 (9) · e0001989

DOI: 10.1371/journal.pgph.0001989 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Global Public Health, online erschienen am 01.09.2023. Verfasst von Elise De Vos und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Antwerp, Antwerp, Belgium. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fonds Wetenschappelijk Onderzoek, Office of AIDS Research.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Studies assessing patient-centred outcomes of novel rifampicin resistant tuberculosis (RR-TB) diagnostics are rare and mostly apply conventional methods which may not adequately address biases. Even though the Xpert MTB/RIF molecular assay was endorsed a decade ago for simultaneous diagnosis of tuberculosis and RR-TB, the impact of the assay on mortality among people with RR-TB has not yet been assessed. We analysed data of an observational prospective cohort study (EXIT-RIF) performed in South Africa. We applied a causal inference approach using inverse odds of sampling weights to rectify survivor bias and selection bias caused by differing screening guidelines. We also adjusted for confounding using a marginal structural model with inverse probability of treatment weights. We estimated the total effect of an RR-TB diagnosis made by the Xpert assay versus the pre-Xpert diagnostic algorithm (entailing a targeted Line Probe Assay (LPA) among TB-confirmed patients) on two-year mortality and we assessed mediation by RR-treatment initiation. Of the 749 patients diagnosed with RR-TB [247 (33%) by the pre-Xpert diagnostic algorithm and 502 (67%) by the Xpert assay], 42.7% died. Of these, 364 (48.6%) patients died in the pre-Xpert group and 200 (39.8%) in the Xpert group. People diagnosed with RR-TB by the Xpert assay had a higher odds of RR-TB treatment initiation compared to those diagnosed by the targeted LPA-based diagnostic process (OR 2.79; 95%CI 2.19–3.56). Receiving an RR-TB diagnosis by Xpert resulted in a 28% reduction in the odds of mortality within 2 years after presentation to the clinic (OR CI 0.72; 95%CI 0.53–0.99). Causal mediation analysis suggests that the higher rate of RR-TB treatment initiation in people diagnosed by the Xpert assay explains the effect of Xpert on 2-year mortality [natural indirect effect odds ratio 0.90 (95%CI 0.85–0.96). By using causal inference methods in combination with high quality observational data, we could demonstrate that the introduction of the Xpert assay caused a 28% reduction in 2-year odds of mortality of RR-TB. This finding highlights the need for advocacy for a worldwide roll-out of rapid molecular tests. Because the effect is mainly caused by increased RR-TB treatment initiation, health care systems should also ensure timely initiation of effective treatment upon an RR-TB diagnosis.

Autor:innen und Institutionen

  • University of Antwerp, Antwerp, Belgium.
  • University of North Carolina, Chapel Hill, NC, United States of America.
  • University of the Witwatersrand, Johannesburg, South Africa.
  • Instituto Nacional de Saúde, Maputo, Mozambique.
  • National Health Laboratory Service, Johannesburg, South Africa.
  • National Health Laboratory Services, Port Elizabeth, South Africa.

ORCID-Profile: Elise De Vos, Daniel Westreich, Yara Voss de Lima, Pedro da Silva, Annelies Van Rie

Förderung

  • Fonds Wetenschappelijk Onderzoek
  • Office of AIDS Research

Zitieren

APA

De Vos, E., Westreich, D., Scott, L., Voss de Lima, Y., Stevens, W., Hayes, C., da Silva, P., & Van Rie, A. (2023). Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS Global Public Health, 3(9), e0001989. https://doi.org/10.1371/journal.pgph.0001989

Vancouver

De Vos E, Westreich D, Scott L, Voss de Lima Y, Stevens W, Hayes C, et al. Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality. PLOS Global Public Health. 2023;3(9):e0001989. doi:10.1371/journal.pgph.0001989

BibTeX
@article{DeVos2023,
  author = {De Vos, Elise and Westreich, Daniel and Scott, Lesley and Voss de Lima, Yara and Stevens, Wendy and Hayes, Cindy and da Silva, Pedro and Van Rie, Annelies},
  title = {Estimating the effect of a rifampicin resistant tuberculosis diagnosis by the Xpert MTB/RIF assay on two-year mortality},
  journal = {PLOS Global Public Health},
  year = {2023},
  volume = {3},
  number = {9},
  pages = {e0001989},
  doi = {10.1371/journal.pgph.0001989}
}
Kostenlos starten →